PTPN2

Across TCGA pan-cancer cohorts, PTPN2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated PTPN2 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PTPN2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PTPN2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

PDAC, CCRCC, and COAD are the cancer types where PTPN2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	III,IV	0.237	0.879	<.001	53	view →
CCRCC	OS	Quartile	II,III,IV	0.649	0.959	.020	14	view →
COAD	DFS	Quartile	II,III,IV	0.889	1.000	.033	12	view →
HNSC	DFS	Median	All	1.000	0.393	.018	10	view →
LSCC	OS	Tertile	All	0.931	0.707	.008	7	view →
LUAD	DFS	Quartile	II,III,IV	0.653	0.209	.006	3	view →
GBM	OS	Quartile	All	0.380	0.601	.008	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

PTPN2–PDAC (OS)

Open the PDAC breakdown →